05.20.10
A study published in the May issue of Clinical Ophthalmology reveals Mirtogenol, taken with Latanoprost medication, effectively improves blood flow to the eyes in patients with ocular hypertension and aids in further normalizing ocular pressure.
Subjects underwent complete eye exams, which found no signs of primary open angle glaucoma or visual field defects. Subjects were randomly divided into three groups to receive treatments of prescription eye drop medication Latanoprost, Mirtogenol tablets, or a combination of both. Each Mirtogenol tablet contains 40 mg of Pycnogenol and 80 mg of Mirtoselect. Subjects consumed one Mirtogenol tablet once in the morning. Latanoprost was taken as one drop per eye daily in the evening. The patients’ intraocular pressure was measured at the same time in the morning at each visit.
Normal eye pressure ranges from 10-21 mmHg. Ocular hypertension begins at a level greater than 21 mmHg. In the group of subjects taking Mirtogenol alone, the intraocular pressure was lowered from 38.1 to 29 mmHg, whereas in those taking Latanoprost the intraocular pressure decreased from 37.7 to 27.2 mmHg. In the third group of patients who took a combination of Mirtogenol and Latanoprost, the intraocular pressure decreased from 38 to 23 mmHg. The study concluded that the combination of Mirtogenol and Latanoprost was more effective than each constituent alone for lowering intraocular pressure, and also yielded better retinal blood flow.
Mirtogenol, a trademark of Indena S.p.A and Horphag Research Ltd., is a patent-pending, proprietary combination of standardized bilberry extract Mirtoselect and French maritime pine bark extract Pycnogenol. For further information: www.mirtogenol.com
Subjects underwent complete eye exams, which found no signs of primary open angle glaucoma or visual field defects. Subjects were randomly divided into three groups to receive treatments of prescription eye drop medication Latanoprost, Mirtogenol tablets, or a combination of both. Each Mirtogenol tablet contains 40 mg of Pycnogenol and 80 mg of Mirtoselect. Subjects consumed one Mirtogenol tablet once in the morning. Latanoprost was taken as one drop per eye daily in the evening. The patients’ intraocular pressure was measured at the same time in the morning at each visit.
Normal eye pressure ranges from 10-21 mmHg. Ocular hypertension begins at a level greater than 21 mmHg. In the group of subjects taking Mirtogenol alone, the intraocular pressure was lowered from 38.1 to 29 mmHg, whereas in those taking Latanoprost the intraocular pressure decreased from 37.7 to 27.2 mmHg. In the third group of patients who took a combination of Mirtogenol and Latanoprost, the intraocular pressure decreased from 38 to 23 mmHg. The study concluded that the combination of Mirtogenol and Latanoprost was more effective than each constituent alone for lowering intraocular pressure, and also yielded better retinal blood flow.
Mirtogenol, a trademark of Indena S.p.A and Horphag Research Ltd., is a patent-pending, proprietary combination of standardized bilberry extract Mirtoselect and French maritime pine bark extract Pycnogenol. For further information: www.mirtogenol.com
